The localization of cardiac cytofluorescence and tissue levels of doxorubicin (DXR) and doxorubicinol (DXR-ol) were studied in rats treated with a single (9 mg/kg: 1-day study) or 3 weekly doses (3 mg/kg: 7-week study) of the compounds. A striking orange-red fluorescence was observed in cardiac cell nuclei from DXR 1-day rats, whilst heart cells from DXR-ol 1-day rats displayed a faint, diffuse fluorescence. Neither cardiac tissue from DXR nor from DXR-ol 7-week animals showed any drug-specific fluorescence. HPLC assay showed that in DXR 1-day rats the drug was concentrated in the heart, which also contained the endogenously produced DXR-ol. Plasma levels of DXR-ol were initially high in DXR-ol 1-day rats but rapidly decreased with time; ca...
The acute and chronic cardiotoxicity as well as the cytotoxicity of 4'-deoxy-4'-iodo-doxorubicinol (...
A single administration of adriamycin (DXR) 6.0 mg/kg i.v. to rats brings about a biphasic impairmen...
The purpose of this study was to examine the cytotoxicity and cardiotoxicity of the new doxorubicin ...
The localization of cardiac cytofluorescence and tissue levels of doxorubicin (DXR) and doxorubicino...
The discovery of a delayed form of DXR-induced cardiotoxicity raises the question whether the presen...
An investigation was performed in the rat to assess the cardiotoxic effects of exogenous doxorubicin...
This study examined the pharmacokinetic profile of the chemotherapeutic drug doxorubicin (DOX), and ...
A highly sensitive and selective high-performance liquid chromatography (HPLC) method was developed ...
Substantial amounts of adriamycin [23214-92-8] were recovered in various organs after i.p. administ...
The major side-effect of the anthracycline anti-tumor drug adriamycin is a specific, dose-dependent ...
The purpose of this study was to evaluate the optimal timing of ADR-529 administration to protect ra...
Previous investigations, performed on isolated rat atria, showed that the lipophylic spin-trapping a...
The aim of the present study was to evaluate the dose- and time-dependence of the effect displayed b...
Doxorubicin (Dox) is one of the most potent anti-neoplastic agents approved by the Food and Drug Adm...
Many efficacious cancer treatments cause significant cardiac morbidity, yet biomarkers or functional...
The acute and chronic cardiotoxicity as well as the cytotoxicity of 4'-deoxy-4'-iodo-doxorubicinol (...
A single administration of adriamycin (DXR) 6.0 mg/kg i.v. to rats brings about a biphasic impairmen...
The purpose of this study was to examine the cytotoxicity and cardiotoxicity of the new doxorubicin ...
The localization of cardiac cytofluorescence and tissue levels of doxorubicin (DXR) and doxorubicino...
The discovery of a delayed form of DXR-induced cardiotoxicity raises the question whether the presen...
An investigation was performed in the rat to assess the cardiotoxic effects of exogenous doxorubicin...
This study examined the pharmacokinetic profile of the chemotherapeutic drug doxorubicin (DOX), and ...
A highly sensitive and selective high-performance liquid chromatography (HPLC) method was developed ...
Substantial amounts of adriamycin [23214-92-8] were recovered in various organs after i.p. administ...
The major side-effect of the anthracycline anti-tumor drug adriamycin is a specific, dose-dependent ...
The purpose of this study was to evaluate the optimal timing of ADR-529 administration to protect ra...
Previous investigations, performed on isolated rat atria, showed that the lipophylic spin-trapping a...
The aim of the present study was to evaluate the dose- and time-dependence of the effect displayed b...
Doxorubicin (Dox) is one of the most potent anti-neoplastic agents approved by the Food and Drug Adm...
Many efficacious cancer treatments cause significant cardiac morbidity, yet biomarkers or functional...
The acute and chronic cardiotoxicity as well as the cytotoxicity of 4'-deoxy-4'-iodo-doxorubicinol (...
A single administration of adriamycin (DXR) 6.0 mg/kg i.v. to rats brings about a biphasic impairmen...
The purpose of this study was to examine the cytotoxicity and cardiotoxicity of the new doxorubicin ...